Allogene Therapeutics Inc (ALLO)

11:54 AM

Allogene’s SWOT analysis: stock outlook amid clinical delays, promising data By Investing.com - Investing.com India

11:54 AM

11:46 AM

Allogene's SWOT analysis: stock outlook amid clinical delays, promising data - Investing.com

11:46 AM

02:52 AM

Allogene Therapeutics falls after trial delay, rating downgrade post Q1 results - MSN

02:52 AM

Jun 13, 2025

Insider Sell: Deborah Messemer Sells 36,885 Shares of Allogene T - GuruFocus

Jun 13, 2025

Jun 12, 2025

Why Is Allogene Therapeutics (ALLO) Up 52.2% Since Last Earnings Report? - Yahoo Finance

Jun 12, 2025

Jun 12, 2025

Shareholders May Find It Hard To Justify Increasing Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) CEO Compensation For Now - simplywall.st

Jun 12, 2025

Jun 06, 2025

Layoff Tracker: Capsida Downsizes as Part of Shift to Clinical-Stage Company - BioSpace

Jun 06, 2025

Jun 04, 2025

Allogene Therapeutics at Jefferies Conference: Delays and Optimism By Investing.com - Investing.com Canada

Jun 04, 2025

Jun 04, 2025

All You Need to Know About Allogene Therapeutics (ALLO) Rating Upgrade to Buy - Yahoo Finance

Jun 04, 2025

Jun 04, 2025

Allogene Therapeutic's ALLO-316 Shows Durable Responses in Advanced Renal Cell Carcinoma - CRISPR Medicine News

Jun 04, 2025

Jun 03, 2025

Allogene Therapeutics Presents Promising Phase 1 Data for ALLO-316 in Renal Cell Carcinoma - MSN

Jun 03, 2025

Jun 03, 2025

Citi maintains buy rating on Allogene stock following ASCO data - Investing.com Australia

Jun 03, 2025

Jun 02, 2025

Citi maintains buy rating on Allogene stock following ASCO data By Investing.com - Investing.com India

Jun 02, 2025

Jun 01, 2025

Allogene Therapeutics (ALLO) Showcases Promising Data from Phase 1 TRAVERSE Study | ALLO Stock News - GuruFocus

Jun 01, 2025

Jun 01, 2025

Allogene Therapeutics Provides Updated Phase 1 Data Highlighting - GuruFocus

Jun 01, 2025

Jun 01, 2025

Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO | ALLO Stock News - GuruFocus

Jun 01, 2025

Jun 01, 2025

Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO - The Manila Times

Jun 01, 2025

Jun 01, 2025

Allogene Therapeutics Highlights Promising Phase 1 Results of ALLO-316 in Advanced Renal Cell Carcinoma at ASCO 2025 - Nasdaq

Jun 01, 2025

Jun 01, 2025

Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses With Allo-316 In Heavily Pretreated Advanced Renal Cell Carcinoma At ASCO - marketscreener.com

Jun 01, 2025

May 29, 2025

Allogene Therapeutics: Buying Around A Potential ASCO Lazarus Moment - Seeking Alpha

May 29, 2025

May 28, 2025

Allogene Therapeutics: Still Looking Shaky, But Looking To Turn The Corner (Rating Upgrade) - Seeking Alpha

May 28, 2025

May 28, 2025

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Raises Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO) - Defense World

May 28, 2025

May 28, 2025

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World

May 28, 2025

May 27, 2025

Allogene at TD Cowen’s Summit: Strategic Insights on CAR T-Cell Therapy - Investing.com Canada

May 27, 2025

May 26, 2025

Allogene Therapeutics’s SWOT analysis: CAR-T pioneer’s stock faces pivotal year - Investing.com

May 26, 2025

May 24, 2025

Analysts Are Bullish on These Healthcare Stocks: Cidara Therapeutics (CDTX), Merus (MRUS) - The Globe and Mail

May 24, 2025

May 23, 2025

Allogene Therapeutics Announces Participation in Upcoming Invest - GuruFocus

May 23, 2025

May 23, 2025

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences - The Manila Times

May 23, 2025

May 23, 2025

Allogene Therapeutics Lines Up Strategic Presentations at Goldman Sachs, Jefferies Healthcare Events - Stock Titan

May 23, 2025

May 23, 2025

Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel - The Manila Times

May 23, 2025

May 23, 2025

Allogene shares update on CAR T-cell therapies at ASCO meeting - Investing.com Australia

May 23, 2025

May 22, 2025

Allogene Therapeutics Announces ASCO 2025 Abstract Publication F - GuruFocus

May 22, 2025

May 22, 2025

Allogene shares update on CAR T-cell therapies at ASCO meeting By Investing.com - Investing.com South Africa

May 22, 2025

May 22, 2025

Allogene Therapeutics Announces Upcoming Presentations at ASCO 2025 Featuring ALLO-316 and ALPHA3 Trial Data - Nasdaq

May 22, 2025

May 22, 2025

Undervalued Opportunities: 3 Penny Stocks With Market Caps Above $30M - simplywall.st

May 22, 2025

May 22, 2025

Allogene extends cash runway into 2027 while prioritizing ALPHA3 and clinical momentum - MSN

May 22, 2025

May 21, 2025

Finance Watch: Prime, Kyverna, Allogene And More Announce Job Cuts - insights.citeline.com

May 21, 2025

May 17, 2025

Citigroup Issues Pessimistic Forecast for Allogene Therapeutics (NASDAQ:ALLO) Stock Price - Defense World

May 17, 2025

May 16, 2025

Regeneron defeats Amgen in PCSK9 case; 2 cell therapy biotechs cut staff - BioPharma Dive

May 16, 2025

May 15, 2025

Allogene (ALLO) Sinks 16% on Downgrade, Trial Delays - GuruFocus

May 15, 2025

May 15, 2025

ALLO: Citigroup Lowers Price Target But Maintains Buy Rating | A - GuruFocus

May 15, 2025

May 15, 2025

Allogene Therapeutics (ALLO) Loses -31.94% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance

May 15, 2025